SENNA PLUS STANDARDIZED SENNA CONCENTRATE 8.6 MG AND DOCUSATE SODIUM 50 MG EACH- docusate sodium,sennosides tablet, film coated
medsource pharmaceuticals

Disclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.

Senna Plus Tablets

Drug Facts

Active ingredients (in each tablet)

Docusate Sodium 50 mg

Sennosides 8.6 mg

Purposes

Stool softener

Laxative

Uses

- relieves occasional constipation (irregularity)
- generally produces a bowel movement in 6-12 hours

Warnings

Do not use

- if you are now taking mineral oil, unless directed by a doctor
- laxative products for longer than 1 week unless directed by a doctor

Ask a doctor before use if you have

- stomach pain
- nausea
- vomiting
- noticed a sudden change in bowel habits that continues over a period of 2 weeks

Stop use and ask a doctor if you have rectal bleeding or fail to have a bowel movement after use of a laxative.

These may indicate a serious condition.

If pregnant or breast-feeding, ask a health professional before use.

Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away.

Directions

- take preferably at bedtime or as directed by a doctor

age	starting dose	maximum dose
adults and children 12 years and older	2 tablets once a day	4 tablets twice a day
children 6 to under 12 years	1 tablet once a day	2 tablets twice a day
children 2 to under 6 years	1/2 tablet once a day	1 tablet twice a day
children under 2 years	ask a doctor	ask a doctor

Other information

- each tablet contains: **calcium 20 mg**
- each tablet contains: **sodium4 mg**
- store at room temperature in a dry place
- keep lid tightly closed

Inactive ingredients Croscarmellose sodium, D&C yellow #10, dextrose, dicalcium phosphate, FD&C yellow #6, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, silica, sodium benzoate, stearic acid, titanium dioxide.

Questions? If you have any questions or comments, or to report an adverse event, please contact **(800) 795-9775**.

DO NOT USE IF IMPRINTED SAFETY SEAL UNDER CAP IS BROKEN OR MISSING

Distributed by:

Plus Pharma

Commack, NY 11725

Manufactured in a GMP facility in the USA



SENNA PLUS STANDARDIZED SENNA CONCENTRATE 8.6 MG AND DOCUSATE SODIUM 50 MG EACH

docusate sodium,sennosides tablet, film coated

Product Information			
Product Type	HUMAN OTC DRUG	**Item Code (Source)**	NDC:45865-938(NDC:51645-850)
Route of Administration	ORAL		

Active Ingredient/Active Moiety		
Ingredient Name	**Basis of Strength**	**Strength**
DOCUSATE SODIUM (UNII: F05Q2T2JA0) (DOCUSATE - UNII:M7P27195AG)	DOCUSATE SODIUM	50 mg
SENNOSIDES (UNII: 3FYP5M0IJX) (SENNOSIDES - UNII:3FYP5M0IJX)	SENNOSIDES	8.6 mg

Inactive Ingredients	
Ingredient Name	**Strength**

CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)	
D&C YELLOW NO. 10 (UNII: 35SW5USQ3G)	
DEXTROSE (UNII: IY9XDZ35W2)	
CALCIUM PHOSPHATE, DIBASIC, DIHYDRATE (UNII: O7TSZ97GEP)	
FD&C YELLOW NO. 6 (UNII: H77VEI93A8)	
HYPROMELLOSES (UNII: 3NXW29V3WO)	
MAGNESIUM STEARATE (UNII: 70097M6I30)	
CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)	
POLYETHYLENE GLYCOL, UNSPECIFIED (UNII: 3WJQ0SDW1A)	
SILICON DIOXIDE (UNII: ETJ7Z6XBU4)	
SODIUM BENZOATE (UNII: OJ245FE5EU)	
STEARIC ACID (UNII: 4ELV7Z65AP)	
TITANIUM DIOXIDE (UNII: 15FIX9V2JP)	

Product Characteristics

Color	orange	**Score**	no score
Shape	ROUND (Biconvex)	**Size**	10mm
Flavor		**Imprint Code**	G55
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:45865-938-30	30 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	12/12/2018	

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
OTC monograph not final	part334	03/27/2006	

Labeler - medsource pharmaceuticals (833685915)

Establishment

Name	Address	ID/FEI	Business Operations
medsource pharmaceuticals		833685915	repack(45865-938)

Revised: 12/2019 medsource pharmaceuticals